Filing Analysis
Nkarta, Inc. announced the upcoming release of its financial results for the second quarter ended June 30, 2026. The filing serves as a formal notice that a press release containing corporate highlights and financial data will be issued on August 10, 2026.
📋 Key Facts
- Company to issue Q2 2026 financial results on August 10, 2026.
- Reporting period ends June 30, 2026.
- The filing includes a press release titled 'Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights' as Exhibit 99.1.
Nkarta, Inc. reported the results of its 2026 annual meeting of stockholders held on June 10, 2026. The meeting included the election of Class III directors, ratification of the independent auditor, and advisory votes on executive compensation.
📋 Key Facts
- Elected Class III directors Ali Behbahani, M.D., M.B.A. and Zachary Scheiner, Ph.D. to serve until the 2029 annual meeting.
- Ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Approved executive compensation on a non-binding advisory basis (43,493,065 votes For).
- Determined to hold future advisory votes on executive compensation every year based on stockholder voting results.
Nkarta, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release. The filing includes corporate highlights and standard financial performance disclosures for the period.
📋 Key Facts
- The filing was made on May 12, 2026.
- Financial results pertain to the first quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- Exhibit 99.1 contains the full press release titled 'Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights'.
Nkarta, Inc. has entered into a sales agreement with Stifel, Nicolaus & Company to establish an at-the-market (ATM) offering program for up to $100 million of its common stock. This allows the company to sell shares periodically at its discretion to raise capital.
🚩 Red Flags
- Potential for significant shareholder dilution
- Need for substantial capital infusion often precedes high cash burn in biotech
📋 Key Facts
- Entered into a Sales Agreement with Stifel on March 25, 2026
- Aggregate offering price of up to $100,000,000
- Sales agent commission is up to 3% of gross proceeds
- Shares will be sold under a Form S-3 registration statement (File No. 333-294611)
Nkarta, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a formal disclosure of the company's year-end performance and corporate highlights via a press release.
📋 Key Facts
- Financial results reported for the period ending December 31, 2025.
- The report was filed on March 25, 2026.
- The filing includes Exhibit 99.1, a press release detailing corporate highlights and financial performance.
- Information provided under Item 2.02 is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Nkarta, Inc. filed an 8-K to announce its financial results for the third quarter ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings and corporate highlights.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2025.
- Filing date: November 10, 2025.
- The company is an emerging growth company.
- Financial results were released via press release (Exhibit 99.1).
Nkarta, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2025. The filing serves as a formal announcement of the earnings release and corporate highlights.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025.
- Filing date: August 12, 2025.
- The company is an emerging growth company.
- Financial results and corporate highlights were released via Exhibit 99.1.
Nkarta, Inc. announced the resignation of its Chief Medical Officer and Head of R&D, Dr. David Shook, effective June 6, 2025. The company has appointed Dr. Shawn Rose to succeed him starting June 23, 2025, with Dr. Shook providing transition support as a consultant through July 11, 2025.
🚩 Red Flags
- Departure of a key executive (CMO/Head of R&D) is often a risk factor for biotech companies during critical clinical stages.
- The resignation was effective immediately/shortly after notice, though mitigated by a consulting agreement.
📋 Key Facts
- Dr. David Shook resigned as CMO and Head of R&D on June 3, 2025, to pursue other opportunities in oncology.
- Dr. Shawn Rose, M.D. Ph.D., appointed as successor effective June 23, 2025.
- Dr. Shook will serve as a consultant under an hourly rate agreement through July 11, 2025.
- Stockholders ratified the appointment of Ernst & Young LLP as independent auditors for the year ending Dec 31, 2025.
- Three Class II directors (Michael Dybbs, Simeon George, and Leone Patterson) were elected to terms ending in 2028.
Nkarta, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025. The filing serves as a formal notification of the release of quarterly earnings and corporate highlights.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2025
- Filing date: May 14, 2025
- The filing includes a press release (Exhibit 99.1) detailing financial results and corporate highlights.
- Company is an emerging growth company.
Nkarta, Inc. has announced a significant workforce reduction of 34% (53 positions) to pivot resources toward its NKX019 program for autoimmune diseases and extend cash runway into 2029. The company is also undergoing leadership changes, including the departure of its Chief Financial and Business Officer.
🚩 Red Flags
- Significant workforce reduction (34%) indicating aggressive cost-cutting/restructuring.
- Departure of the Chief Financial and Business Officer.
- Strategic pivot involving the deprioritization of existing clinical programs (NKX101).
- High restructuring costs ($5.5M-$6.5M) impacting near-term earnings.
📋 Key Facts
- Workforce reduction affecting approximately 34% of employees (53 positions).
- Estimated restructuring costs between $5.5 million and $6.5 million to be recognized primarily in Q1 2025.
- Cost-cutting measures intended to extend cash runway into 2029.
- Deprioritization of NKX101 and NKX019 for non-Hodgkin lymphoma development.
- Focus shifted to NKX019 for autoimmune diseases, with clinical data updates expected in H2 2025.
- Chief Financial and Business Officer Alyssa Levin is departing effective March 31, 2025; she will serve as a consultant for up to three months.
- Nadir Mahmood, Ph.D. (President) appointed as interim Principal Financial Officer and Principal Accounting Officer.
Nkarta, Inc. filed an 8-K to announce its third quarter 2024 financial results for the period ended September 30, 2024.
📋 Key Facts
- Company reported Q3 2024 financial results on November 7, 2024.
- The filing includes a press release (Exhibit 99.1) detailing corporate highlights and financial performance.
- The company is an emerging growth company.
This is an amendment (8-K/A) to a previously filed 8-K. The purpose of the filing is to correct an administrative error in the submission header, changing the item designation from Item 1.01 to Items 2.02 and 9.01 regarding the reporting of Q2 2024 financial results.
🚩 Red Flags
- None identified; this is a purely administrative correction of an error in the header.
📋 Key Facts
- The filing corrects a clerical error where the original 8-K (filed August 13, 2024) incorrectly cited Item 1.01.
- The correct items for the reported information are Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
- All substantive disclosures from the original filing remain unchanged.
- The report concerns financial results for the second quarter ended June 30, 2024.
Nkarta, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2024. The filing serves as a formal notification of the release of quarterly earnings and corporate highlights.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2024.
- Filing date: August 13, 2024.
- The filing includes a press release (Exhibit 99.1) detailing financial results and corporate highlights.
Nkarta, Inc. announced a leadership reorganization effective July 29, 2024, featuring the appointment of Dr. Nadir Mahmood as President and several executive transitions within the scientific leadership team.
🚩 Red Flags
- Executive turnover in the scientific leadership (CSO moving to an advisory role) can sometimes indicate internal shifts or strategic pivots.
📋 Key Facts
- Dr. Nadir Mahmood appointed as President, effective July 29, 2024.
- Dr. Mahmood's compensation includes a $530,000 annual base salary and a target annual bonus of 50% of base salary.
- Grant of stock options to Dr. Mahmood for 550,000 shares of common stock with a vesting schedule starting July 29, 2025.
- David R. Shook, M.D. promoted to Chief Medical Officer and Head of Research and Development.
- James Trager, Ph.D. transitioning from Chief Scientific Officer to a special advisory role.
Nkarta, Inc. announced the FDA clearance of an Investigational New Drug (IND) application for NKX019 to treat three new autoimmune indications: systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis. Additionally, the company reported progress in its clinical trial for lupus nephritis (LN), noting that the first patient has been screened.
📋 Key Facts
- FDA cleared IND application for NKX019 to evaluate treatment for systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis.
- Clinical trial update: The company has successfully screened the first patient for its NKX019 trial in patients with refractory lupus nephritis (LN).
- The filing includes a press release regarding pipeline expansion into additional autoimmune indications.
Nkarta, Inc. held its 2024 annual meeting of stockholders on June 13, 2024, resulting in the election of three directors and the ratification of Ernst & Young LLP as independent auditors. Crucially, stockholders approved an amendment to increase authorized common stock from 100 million to 200 million shares.
🚩 Red Flags
- Significant increase in authorized share count (doubled from 100M to 200M), which typically facilitates future equity dilution via secondary offerings or warrants.
📋 Key Facts
- Annual meeting held on June 13, 2024.
- Stockholders approved increasing total authorized common stock from 100,000,000 to 200,000,000 shares.
- Three Class I directors elected: Paul Hastings, Angela Thedinga, and George Vratsanos.
- Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending Dec 31, 2024.
- Amendment to Certificate of Incorporation became effective June 13, 2024.
Nkarta, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal announcement of quarterly earnings and corporate highlights.
📋 Key Facts
- Report covers the fiscal quarter ended March 31, 2024.
- The company is an emerging growth company.
- Financial results were released via press release on May 9, 2024.
Nkarta, Inc. completed a significant equity offering consisting of 21,010,000 common shares and 3,000,031 pre-funded warrants at approximately $10.00 per share. The transaction is expected to net the company roughly $225.2 million in proceeds.
🚩 Red Flags
- Significant dilution: The issuance of over 24 million total securities (shares + warrants) represents a substantial increase in the company's float.
📋 Key Facts
- Offered 21,010,000 shares of common stock at $10.00 per share.
- Offered 3,000,031 pre-funded warrants at $9.9999 per warrant.
- Net proceeds estimated at approximately $225.2 million after expenses and commissions.
- Proceeds are earmarked for NKX019 research/clinical development, manufacturing buildout, and working capital.
- The offering was conducted under a previously effective Form S-3 registration statement (effective May 5, 2023).
- Warrants have an exercise price of $0.0001 per share.
Nkarta, Inc. released updated clinical data from its Phase 1 study of NKX019 in patients with non-Hodgkin lymphoma (NHL). The data focuses on B cell reconstitution patterns and preliminary pharmacokinetic results comparing different lymphodepletion regimens.
📋 Key Facts
- Released updated clinical data for NKX019 in a Phase 1 study for non-Hodgkin lymphoma (NHL) on March 25, 2024.
- Observed rapid depletion of circulating CD19 positive cells following treatment with NKX019.
- In patients remaining in remission (n=5), B-cell repertoire recovered at 3 months post-treatment with a predominance of naïve, non-class-switched isotypes.
- B-cell recovery was confirmed via single-cell RNA profiling showing transcriptome profiles of naïve and intermediate B cells.
- Preliminary pharmacokinetic (PK) data showed similar peak exposure for patients regardless of whether they received fludarabine/cyclophosphamide or cyclophosphamide alone as lymphodepletion.
- The study included two patients treated using a compressed dosing regimen.
Nkarta, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2023. The filing serves as a formal announcement of the company's quarterly earnings performance.
📋 Key Facts
- Reporting period: Fourth quarter and full year ended December 31, 2023.
- Filing date: March 21, 2024.
- The filing includes a press release (Exhibit 99.1) detailing financial results and corporate highlights.
Nkarta, Inc. released an updated corporate presentation to reflect recent business and strategic updates. This filing is a standard Regulation FD disclosure intended for use in investor meetings.
📋 Key Facts
- Company released an updated corporate presentation dated January 2024.
- The presentation contains business and strategic updates.
- Information was made available via Exhibit 99.1 and the company's website.